Litcius/Paper detail

Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC

Xiuning Le, Monique B. Nilsson, Jonathan W. Goldman, Martin Reck, Kazuhiko Nakagawa, T. Kato, Luis Paz Ares, Bente Frimodt‐Moller, Katharina Wolff, Carla Visseren‐Grul, John V. Heymach, Edward B. Garon

2020Journal of Thoracic Oncology331 citationsDOI

Topics & Concepts

MedicineBevacizumabRamucirumabCancer researchCarcinogenesisEpidermal growth factor receptorOncologyInternal medicineVEGF receptorsCancerChemotherapyLung Cancer Treatments and MutationsColorectal Cancer Treatments and StudiesLymphoma Diagnosis and Treatment
Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC | Litcius